FORTIS Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,545 Cr
verified against source
Revenue YoY
17.5%
reported change
EBITDA
₹568 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fortis Healthcare delivered a steady Q1 FY27 with consolidated revenue of INR 2,545 crore (+17.5% YoY), driven by robust hospital segment growth of 19% to INR 2,187 crore. EBITDA margin contracted 30bps YoY to 22.3% due to new facility ramp-up costs and one-time legal expenses, though management reiterated its FY28 target of 25% EBITDA margin. Hospital occupancy remained stable at 69% with occupied beds growing 17% to 3,418, while ARPO increased 2.6% to INR 2.71 lakh. Key specialties like renal sciences (+28%), neurosciences (+27%), and orthopedics (+23%) drove outperformance. The newly launched ESOP scheme ( INR 40 crore quarterly charge) aims to align doctor incentives and reduce attrition, with management confident this will offset costs through improved operational efficiency. Diagnostics business showed 10.2% growth with margin expansion to 23.9%. Management guided for 400 additional operational beds in remaining quarters and a proton therapy facility at Gurugram ( INR 250+ crore capex). Oncology growth moderation to ~10-12% from 27% due to CGHS/ECHS chemotherapy pricing changes remains a key monitorable. The 25% margin guidance by FY28 appears achievable if new facilities scale as expected, though Glen Eagles stabilization may take another 2-4 quarters.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated its medium-term target of 25% EBITDA margin (including ESOP costs), driven by new facility ramp-up, margin expansion at underperforming hospitals (Manesar, NOIDA), and operational efficiencies.
- Company added 100 beds in Q1 and expects 400 more beds in remaining quarters, with major contribution from FMRI (200 beds pending occupancy certificate) and other brownfield expansions.
- ESOP charge estimated at INR 40 crore per quarter for FY27, declining to INR 30 crore per quarter in FY28 and INR 25 crore per quarter in FY29, based on current vesting schedule.
- Diagnostics business targeting 12-13% revenue growth and 24-25% EBITDA margin, with focus on improving B2C mix and specialized/ preventive portfolio contribution.
Risks flagged
- CGHS/ECHS chemotherapy drug pricing mechanism mandating 30% discount on MRP has significantly impacted oncology revenue growth, reducing it from ~27% to ~10-12%. This disproportionately affected hospitals with large government scheme beneficiary bases (Punjab, Jaipur, Delhi NCR).
- Management indicated Glen Eagles hospitals (under O&M) are not yet fully stabilized and may take another 2-4 quarters to reach Fortis portfolio standards. Currently generating ~INR 6 crore management fee per quarter.
- Analyst raised concern about Agilus growing at 10% while industry peers grow at 15%, potentially indicating competitive weakness despite new leadership. Management acknowledged muted growth period due to brand transition but committed to reviving performance.
- Net debt increased to INR 2,233 crore (1.01x EBITDA ratio vs 0.92x YoY) primarily due to prior year acquisitions, increasing financial leverage risk in a rising interest rate environment.
Key quotes
- The idea was that the doctors participate in the growth of the organizations and their interests and the company's interests are aligned. Clinicians help in many ways for the performance to improve in terms of controlling of the consumption for instance, other efficiency measures which are necessary to have a better profitability profile.
- Oncology growth has become muted because of the CGHS/ECHS pricing and also our base has been increasing continuously. Since the growth was very high for about four to five years, the base has also become very large. We feel that oncology is going to be a big growth driver in terms of volumes but it is going to be in the range of 10-12% and not like 27% which used to be earlier.
- We recognize that there has been a muted growth or rather a stagnant period for some time and that was a variety of factors including the brand change. Now those things are getting stabilized. We have about 10% growth seen in the last quarter and a lot of it has come from volume growth as well. This is definitely a sign of revival.
Research modules